Research Analysts Set Expectations for ETON Q3 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Research analysts at B. Riley upped their Q3 2025 earnings per share (EPS) estimates for shares of Eton Pharmaceuticals in a research note issued on Wednesday, March 19th. B. Riley analyst M. El-Saadi now forecasts that the company will earn $0.14 per share for the quarter, up from their prior forecast of $0.04. B. Riley currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.44 EPS, FY2026 earnings at $1.08 EPS, FY2027 earnings at $1.45 EPS, FY2028 earnings at $1.66 EPS and FY2029 earnings at $1.82 EPS.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, meeting analysts’ consensus estimates of ($0.02). The firm had revenue of $11.65 million for the quarter, compared to analysts’ expectations of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%.

A number of other analysts have also recently issued reports on ETON. HC Wainwright reissued a “buy” rating and set a $33.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday. Craig Hallum increased their price objective on Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday.

Eton Pharmaceuticals Stock Performance

Shares of ETON opened at $14.22 on Friday. The stock’s 50-day simple moving average is $15.58 and its 200 day simple moving average is $11.58. The stock has a market capitalization of $370.45 million, a price-to-earnings ratio of -64.64 and a beta of 1.37. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $18.41.

Hedge Funds Weigh In On Eton Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. bought a new position in Eton Pharmaceuticals in the 3rd quarter worth about $54,000. Tower Research Capital LLC TRC bought a new position in Eton Pharmaceuticals in the 4th quarter worth about $86,000. Jane Street Group LLC bought a new position in Eton Pharmaceuticals in the 3rd quarter worth about $90,000. Jefferies Financial Group Inc. bought a new position in Eton Pharmaceuticals in the 4th quarter worth about $133,000. Finally, Raymond James Financial Inc. bought a new position in Eton Pharmaceuticals in the 4th quarter worth about $147,000. 27.86% of the stock is currently owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.